IN10018 clinical trials
IN10018 is named as an intervention in 13 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is InxMed (Shanghai) Co., Ltd (8). The most-studied condition is NSCLC.
How IN10018 works
All drug targets →- Focal adhesion kinase 1 inhibitor InhibitorTarget: PTK2 protein tyrosine kinase 2ChEMBL only
- Non-small cell lung carcinomaPhase 3
- Fallopian tube cancerPhase 2
- Ovarian cancerPhase 2
- Primary peritoneal carcinomaPhase 2
- Colorectal cancerPhase 1/2
- Exocrine pancreatic carcinomaPhase 1/2
- MelanomaPhase 1/2
- NeoplasmPhase 1/2
- Pancreatic ductal adenocarcinomaPhase 1/2
- Small cell lung carcinomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3657311, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12369, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for IN10018
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of IN10018
13 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with IN10018
14 conditionsAll 14 conditions
| Condition (as registered) | Trials |
|---|---|
| NSCLC | 2 |
| Solid Tumor | 2 |
| Pancreatic Cancer | 1 |
| NSCLC (Advanced Non-small Cell Lung Cancer) | 1 |
| Platinum-resistant Ovarian Cancer | 1 |
| Solid Tumor Cancer | 1 |
| PDAC | 1 |
| Ovarian Cancer Recurrent | 1 |
| Cervical Adenocarcinoma | 1 |
| Gastric-type Endocervical Adenocarcinoma | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Biliary Tract Cancer | 1 |
| Melanoma | 1 |
| Small Cell Lung Cancer Extensive Stage | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| InxMed (Shanghai) Co., Ltd | 8 |
| Jemincare | 1 |
| InventisBio Co., Ltd | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Shanghai Jeyou Pharmaceutical Co., Ltd | 1 |
| Hangzhou Hanx Biopharmaceuticals, Ltd | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 13 | 10 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about IN10018 trials
How many clinical trials are testing IN10018?
13 current trials in our China register name IN10018 (also registered as BI 853520) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are IN10018 trials recruiting patients?
Yes. 10 of the 13 trials are recruiting: 10 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors IN10018 clinical trials?
InxMed (Shanghai) Co., Ltd (8), Jemincare (1), InventisBio Co., Ltd (1) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IN10018 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IN10018 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IN10018 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.